Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Conceptual problems, ideology clashes and xenophobia prevented the concept of zero from catching on for a long time. Today ...

Vertex also picked up a positive Committee for Medicinal Products for Human Use (CHMP) opinion for Alyftrek. As a result, it's looking for European Commission approval for the drug in the second half ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Founded in 2021 by former engineers at Amazon Web Services, Row Zero is designed as an alternative to traditional spreadsheet ...

Vertex Pharmaceuticals (NASDAQ:VRTX) missed on the top and bottom lines in its Q1 financial results and also raised the low ...

In a recent study, researchers from Curtin University and the Geological Survey of Western Australia unearthed compelling ...

Showcase your company news with guaranteed exposure both in print and online The Future of Bay Area Biotech: Searching For Answers The Small Business Leaders awards program honors the dedicated ...

Vertex Pharmaceuticals hit a rough patch in Q1, reporting weaker-than-expected earnings and halting an early mRNA cystic ...

a vertex list and a list of faces. This library makes it easier to construct polyhedra by providing functions to construct, merge, and modify VNF data, while avoiding common pitfalls such as reversed ...